Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Brian Kavanagh

Concepts (624)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Radiosurgery
81
2023
298
12.860
 Why?
Radiation Oncology
28
2022
76
7.080
 Why?
Lung Neoplasms
59
2023
2207
4.230
 Why?
Prostatic Neoplasms
29
2020
927
3.650
 Why?
Brain Neoplasms
34
2023
980
3.440
 Why?
Carcinoma, Non-Small-Cell Lung
28
2023
963
2.850
 Why?
Radiotherapy
17
2016
177
2.690
 Why?
Liver Neoplasms
21
2019
521
2.640
 Why?
Neoplasms
28
2021
2118
2.380
 Why?
Radiotherapy Planning, Computer-Assisted
30
2023
118
2.180
 Why?
Radiotherapy Dosage
44
2023
246
2.060
 Why?
Radiotherapy, Conformal
17
2017
68
2.020
 Why?
Radiation Injuries
16
2018
127
1.940
 Why?
Radiotherapy, Intensity-Modulated
16
2019
123
1.930
 Why?
Glioblastoma
12
2016
253
1.920
 Why?
Small Cell Lung Carcinoma
6
2023
77
1.670
 Why?
Four-Dimensional Computed Tomography
7
2021
25
1.540
 Why?
Cranial Irradiation
7
2020
66
1.520
 Why?
Cone-Beam Computed Tomography
9
2023
26
1.410
 Why?
Brachytherapy
14
2016
104
1.400
 Why?
Dacarbazine
9
2016
100
1.320
 Why?
Pulmonary Ventilation
5
2021
68
1.220
 Why?
Humans
216
2023
115741
1.200
 Why?
Aged
97
2023
19294
1.200
 Why?
Chemoradiotherapy
8
2020
187
1.150
 Why?
Antineoplastic Agents, Alkylating
6
2016
68
1.150
 Why?
Societies, Medical
9
2021
684
1.120
 Why?
Radiotherapy, Adjuvant
8
2015
182
1.110
 Why?
Middle Aged
100
2023
27069
1.020
 Why?
Aged, 80 and over
52
2020
6423
0.950
 Why?
Uterine Cervical Neoplasms
9
2016
213
0.920
 Why?
SEER Program
10
2018
195
0.920
 Why?
Neoplasm Metastasis
10
2020
526
0.870
 Why?
Neoplasm Recurrence, Local
14
2014
863
0.870
 Why?
Radiation Oncologists
2
2022
4
0.850
 Why?
Male
109
2023
56050
0.850
 Why?
Radiation Pneumonitis
6
2021
24
0.820
 Why?
Radiometry
10
2022
43
0.810
 Why?
Neoplasm Staging
24
2018
1178
0.810
 Why?
Databases, Factual
10
2017
1139
0.810
 Why?
Internship and Residency
5
2022
951
0.790
 Why?
Dose-Response Relationship, Radiation
20
2021
130
0.790
 Why?
Registries
5
2018
1770
0.770
 Why?
Whole-Body Irradiation
4
2020
72
0.770
 Why?
Neoplasm Grading
6
2016
244
0.760
 Why?
Social Media
2
2020
135
0.750
 Why?
United States
31
2022
12304
0.730
 Why?
Liver
9
2018
1690
0.730
 Why?
Medicine
2
2021
103
0.710
 Why?
Videoconferencing
1
2020
57
0.700
 Why?
Travel
1
2020
121
0.680
 Why?
Carcinoma, Squamous Cell
8
2007
577
0.670
 Why?
Scattering, Radiation
5
2022
91
0.670
 Why?
Radiation
1
2019
24
0.660
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
3
2009
140
0.660
 Why?
Female
97
2023
60018
0.660
 Why?
Models, Economic
1
2019
48
0.650
 Why?
Respiratory Function Tests
3
2023
535
0.650
 Why?
Carcinoma, Renal Cell
5
2015
168
0.640
 Why?
Breast Neoplasms
11
2022
1872
0.640
 Why?
Combined Modality Therapy
24
2019
1127
0.640
 Why?
Insurance, Health, Reimbursement
1
2019
88
0.630
 Why?
Treatment Outcome
32
2023
9162
0.630
 Why?
Astrocytoma
4
2014
109
0.630
 Why?
Kidney Neoplasms
6
2015
326
0.630
 Why?
Adult
68
2023
30789
0.610
 Why?
Antineoplastic Agents, Immunological
2
2019
154
0.610
 Why?
Faculty, Medical
1
2020
234
0.600
 Why?
Lung
10
2023
3673
0.590
 Why?
Stereotaxic Techniques
3
2006
28
0.590
 Why?
Prostate-Specific Antigen
8
2016
151
0.560
 Why?
Antineoplastic Agents
13
2023
1893
0.560
 Why?
Neoplasms, Second Primary
2
2008
91
0.550
 Why?
Preoperative Care
1
2018
319
0.550
 Why?
Quality of Life
6
2021
2388
0.540
 Why?
Radiotherapy, Computer-Assisted
6
2015
12
0.530
 Why?
Insurance Coverage
4
2019
204
0.520
 Why?
Models, Biological
8
2018
1646
0.510
 Why?
Organs at Risk
5
2021
30
0.510
 Why?
Androgen Antagonists
6
2020
69
0.500
 Why?
Prospective Studies
22
2023
6276
0.500
 Why?
Disease-Free Survival
12
2019
621
0.490
 Why?
Oligodendroglioma
1
2014
15
0.490
 Why?
Magnetic Resonance Imaging
9
2023
3122
0.470
 Why?
Observational Studies as Topic
1
2015
90
0.470
 Why?
Radiation Tolerance
6
2015
92
0.470
 Why?
Immunologic Factors
1
2016
220
0.470
 Why?
Health Physics
2
2016
4
0.460
 Why?
Clinical Trials as Topic
9
2017
941
0.460
 Why?
Checklist
1
2015
84
0.460
 Why?
Perfusion Imaging
1
2014
55
0.460
 Why?
Beauty
1
2013
11
0.460
 Why?
Protein Kinase Inhibitors
6
2019
790
0.450
 Why?
Antineoplastic Combined Chemotherapy Protocols
11
2019
1361
0.450
 Why?
Spiral Cone-Beam Computed Tomography
2
2023
3
0.440
 Why?
Phantoms, Imaging
5
2023
138
0.440
 Why?
Retrospective Studies
34
2023
12633
0.440
 Why?
ErbB Receptors
10
2023
557
0.440
 Why?
Artifacts
4
2019
123
0.440
 Why?
Medicare
4
2021
668
0.430
 Why?
Oxygen
5
2016
837
0.430
 Why?
Credentialing
1
2012
12
0.430
 Why?
Liver Regeneration
2
2012
32
0.430
 Why?
Kaplan-Meier Estimate
11
2019
816
0.420
 Why?
Proton Therapy
2
2015
10
0.420
 Why?
Survival Analysis
11
2020
1219
0.400
 Why?
Follow-Up Studies
18
2019
4442
0.400
 Why?
Antibodies
2
2018
374
0.400
 Why?
Hemoglobin A
2
2002
21
0.390
 Why?
Rectum
4
2014
151
0.390
 Why?
Consensus
4
2022
537
0.390
 Why?
Survival Rate
13
2019
1651
0.380
 Why?
Lymph Nodes
1
2014
423
0.380
 Why?
Carcinoma
2
2006
200
0.380
 Why?
Relative Biological Effectiveness
2
2008
3
0.370
 Why?
Erlotinib Hydrochloride
4
2019
65
0.360
 Why?
Radiotherapy, High-Energy
2
2008
12
0.360
 Why?
Prognosis
15
2020
3343
0.360
 Why?
Comparative Effectiveness Research
1
2011
130
0.360
 Why?
Skin Neoplasms
2
2015
761
0.350
 Why?
Antigens, Neoplasm
3
2009
223
0.350
 Why?
Neoplastic Stem Cells
1
2013
331
0.340
 Why?
Stomach
1
2010
101
0.340
 Why?
Proportional Hazards Models
9
2019
1088
0.340
 Why?
Positron-Emission Tomography
6
2019
284
0.330
 Why?
Career Choice
2
2021
183
0.330
 Why?
Antigens, CD
2
2009
442
0.330
 Why?
Intestine, Small
1
2010
125
0.330
 Why?
Cell Hypoxia
3
2002
220
0.320
 Why?
Risk Assessment
4
2015
2990
0.310
 Why?
Head and Neck Neoplasms
3
2008
425
0.310
 Why?
Respiratory Mechanics
1
2008
56
0.310
 Why?
Receptor Protein-Tyrosine Kinases
4
2015
225
0.310
 Why?
Medical Oncology
3
2020
230
0.300
 Why?
Quinazolines
6
2014
241
0.300
 Why?
Vision, Ocular
1
2008
30
0.300
 Why?
Radiation Protection
2
2009
35
0.300
 Why?
Carcinoma, Transitional Cell
1
2008
54
0.290
 Why?
Orbit
1
2008
59
0.290
 Why?
Pyrazoles
4
2021
362
0.290
 Why?
Colorectal Neoplasms
4
2017
617
0.290
 Why?
Pyridines
4
2021
425
0.280
 Why?
Spinal Neoplasms
2
2007
29
0.280
 Why?
Prostatectomy
3
2014
98
0.280
 Why?
Bone Neoplasms
4
2019
194
0.280
 Why?
Retroperitoneal Neoplasms
1
2007
22
0.280
 Why?
Linear Models
2
2010
778
0.280
 Why?
Adrenergic alpha-Antagonists
1
2006
30
0.280
 Why?
Radiation-Sensitizing Agents
3
2001
38
0.280
 Why?
Algorithms
7
2017
1500
0.270
 Why?
Urologic Diseases
1
2006
36
0.270
 Why?
Patient Selection
3
2021
654
0.270
 Why?
Cancer Vaccines
1
2007
137
0.270
 Why?
Glomus Jugulare Tumor
1
2006
5
0.270
 Why?
Histocompatibility Antigens Class I
1
2007
174
0.270
 Why?
Melanoma
3
2018
651
0.270
 Why?
Time Factors
9
2021
6171
0.270
 Why?
Tumor Burden
9
2014
261
0.260
 Why?
Immunotherapy, Adoptive
1
2007
194
0.260
 Why?
T-Lymphocytes, Regulatory
1
2008
342
0.250
 Why?
Necrosis
4
2022
210
0.250
 Why?
Urinary Bladder Neoplasms
1
2008
197
0.250
 Why?
Central Nervous System
3
2023
239
0.250
 Why?
Practice Guidelines as Topic
5
2021
1405
0.250
 Why?
Lymphocyte Activation
2
2009
1057
0.250
 Why?
Insurance, Health
2
2018
246
0.250
 Why?
CTLA-4 Antigen
3
2018
78
0.250
 Why?
Carcinoma, Hepatocellular
1
2007
224
0.250
 Why?
Pneumonia, Viral
2
2020
344
0.250
 Why?
Coronavirus Infections
2
2020
336
0.250
 Why?
Data Mining
2
2016
100
0.250
 Why?
Signal-To-Noise Ratio
3
2019
58
0.240
 Why?
Tomography, X-Ray Computed
11
2015
2393
0.240
 Why?
Particle Accelerators
3
2019
9
0.240
 Why?
Dendritic Cells
1
2007
438
0.230
 Why?
Propionates
2
2001
33
0.230
 Why?
Rectal Neoplasms
4
2008
122
0.230
 Why?
Chemotherapy, Adjuvant
7
2015
334
0.230
 Why?
Aniline Compounds
2
2001
71
0.220
 Why?
Oncogene Addiction
1
2023
5
0.220
 Why?
Molecular Targeted Therapy
2
2016
348
0.220
 Why?
Inappropriate ADH Syndrome
2
1993
7
0.210
 Why?
Nasopharyngeal Neoplasms
2
1993
14
0.210
 Why?
Propensity Score
4
2018
225
0.210
 Why?
Radiopharmaceuticals
3
2014
187
0.210
 Why?
Radiography
6
2014
828
0.210
 Why?
CD4-Positive T-Lymphocytes
1
2008
965
0.200
 Why?
Fluorodeoxyglucose F18
2
2013
125
0.200
 Why?
Pandemics
2
2020
1335
0.200
 Why?
Analysis of Variance
4
2016
1230
0.200
 Why?
Protein-Tyrosine Kinases
2
2023
396
0.190
 Why?
Pelvis
3
2023
92
0.190
 Why?
Proto-Oncogene Proteins c-ret
1
2021
24
0.190
 Why?
Mass Screening
1
2008
1024
0.190
 Why?
Erythropoietin
1
2001
72
0.190
 Why?
Lymphatic Metastasis
3
2019
276
0.190
 Why?
National Cancer Institute (U.S.)
2
2017
40
0.190
 Why?
Gene Rearrangement
3
2018
135
0.180
 Why?
Pyrimidines
2
2021
376
0.180
 Why?
Palatal Neoplasms
1
2000
4
0.180
 Why?
Anemia
1
2001
144
0.180
 Why?
Technology, Radiologic
2
2010
6
0.180
 Why?
Radiographic Image Enhancement
1
2000
58
0.170
 Why?
Adenocarcinoma
4
2008
799
0.170
 Why?
Proto-Oncogene Proteins
2
2023
609
0.170
 Why?
Electromagnetic Phenomena
1
2019
22
0.170
 Why?
Pelvic Neoplasms
1
1999
19
0.170
 Why?
Relative Value Scales
1
2019
5
0.170
 Why?
Erythrocyte Transfusion
1
2001
187
0.170
 Why?
Suggestion
1
2019
5
0.170
 Why?
Fluoroscopy
1
2000
141
0.170
 Why?
Thoracic Neoplasms
3
2015
33
0.170
 Why?
Cohort Studies
4
2018
4949
0.170
 Why?
Consolidation Chemotherapy
1
2019
9
0.170
 Why?
Clinical Coding
1
2019
20
0.170
 Why?
Radiography, Interventional
1
2000
111
0.170
 Why?
Positron Emission Tomography Computed Tomography
1
2020
70
0.170
 Why?
Patient Care Planning
1
2000
142
0.170
 Why?
Genital Neoplasms, Female
1
2000
73
0.160
 Why?
Epidermal Growth Factor
2
1998
161
0.160
 Why?
Image Processing, Computer-Assisted
3
2019
699
0.160
 Why?
Aquaporin 4
1
2019
86
0.160
 Why?
Farms
1
2018
3
0.160
 Why?
Calcium-Calmodulin-Dependent Protein Kinases
2
1998
171
0.160
 Why?
Policy
1
2019
140
0.150
 Why?
Karnofsky Performance Status
3
2015
36
0.150
 Why?
Health Knowledge, Attitudes, Practice
1
2006
1200
0.150
 Why?
Organ Size
3
2018
434
0.150
 Why?
Risk Factors
7
2016
8702
0.150
 Why?
Industry
1
2018
65
0.150
 Why?
Frontal Lobe
1
1998
139
0.150
 Why?
Urinary Bladder
2
2010
165
0.150
 Why?
Health Priorities
1
2017
34
0.150
 Why?
Radiographic Image Interpretation, Computer-Assisted
2
2015
106
0.150
 Why?
Cell Division
2
1997
759
0.150
 Why?
Multivariate Analysis
3
2019
1441
0.150
 Why?
Immunity, Cellular
1
2019
262
0.150
 Why?
Postoperative Care
2
2017
222
0.150
 Why?
Radiobiology
3
2008
4
0.140
 Why?
Health Planning
1
2017
46
0.140
 Why?
Maximum Tolerated Dose
4
2010
182
0.140
 Why?
Thymus Neoplasms
1
2017
21
0.140
 Why?
Thymoma
1
2017
31
0.140
 Why?
Perioperative Care
1
2018
126
0.140
 Why?
Cause of Death
2
2017
368
0.140
 Why?
Disease Progression
7
2019
2423
0.140
 Why?
Consensus Development Conferences, NIH as Topic
1
2016
2
0.140
 Why?
Flunarizine
2
1993
2
0.140
 Why?
Preoperative Period
1
2017
104
0.140
 Why?
Programmed Cell Death 1 Receptor
1
2018
193
0.140
 Why?
Monitoring, Intraoperative
1
2016
39
0.130
 Why?
Health Expenditures
1
2017
173
0.130
 Why?
Pulmonary Atelectasis
1
2015
12
0.130
 Why?
Glioma
2
2010
296
0.130
 Why?
Gastrointestinal Tract
1
2018
168
0.130
 Why?
Precision Medicine
2
2017
344
0.130
 Why?
Oximetry
1
2016
80
0.130
 Why?
Salvage Therapy
4
2017
128
0.130
 Why?
Neurosurgery
1
2015
26
0.130
 Why?
Clinical Competence
2
2022
912
0.120
 Why?
Evidence-Based Medicine
1
2019
684
0.120
 Why?
Multimodal Imaging
2
2013
99
0.120
 Why?
Induction Chemotherapy
2
2013
56
0.120
 Why?
Intensive Care Units
1
1999
622
0.120
 Why?
Drug Administration Schedule
3
2014
724
0.120
 Why?
Vaginal Neoplasms
1
1994
11
0.120
 Why?
Soft Tissue Neoplasms
1
2015
90
0.120
 Why?
Perineum
1
1994
27
0.120
 Why?
Sensitivity and Specificity
5
2016
1730
0.120
 Why?
Health Services Research
1
2017
377
0.120
 Why?
Quality Control
5
2013
148
0.120
 Why?
Marital Status
1
2014
41
0.120
 Why?
Maytansine
1
2014
13
0.120
 Why?
Ventilation-Perfusion Ratio
1
2014
10
0.120
 Why?
Technetium Tc 99m Pentetate
1
2014
7
0.120
 Why?
Nuclear Medicine
1
2014
7
0.120
 Why?
Incidence
3
2016
2335
0.120
 Why?
Prostate
1
2015
157
0.120
 Why?
Risk
3
2016
819
0.120
 Why?
Cerebrovascular Circulation
1
2016
203
0.120
 Why?
Takayasu Arteritis
1
1994
8
0.120
 Why?
Brain Edema
1
2014
59
0.120
 Why?
Radiotherapy Setup Errors
1
2013
3
0.110
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
15
0.110
 Why?
Health Status Disparities
1
2016
204
0.110
 Why?
Cell Survival
3
2008
1024
0.110
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1147
0.110
 Why?
Piperidines
2
2015
163
0.110
 Why?
Oropharyngeal Neoplasms
1
1994
39
0.110
 Why?
Randomized Controlled Trials as Topic
2
2015
1218
0.110
 Why?
Xerostomia
1
1993
19
0.110
 Why?
Blood Viscosity
1
1993
17
0.110
 Why?
Erythrocytes
2
2001
589
0.110
 Why?
Observer Variation
1
2014
301
0.110
 Why?
Health Care Reform
1
2014
92
0.110
 Why?
Calcium
2
1998
1103
0.110
 Why?
Lactates
1
1993
83
0.110
 Why?
Clinical Decision-Making
1
2015
273
0.110
 Why?
Healthcare Disparities
1
2018
486
0.100
 Why?
Physicians
1
2020
776
0.100
 Why?
Early Detection of Cancer
1
2016
340
0.100
 Why?
Age Factors
2
2021
2911
0.100
 Why?
Partial Pressure
2
2002
28
0.100
 Why?
Motion
2
2011
96
0.100
 Why?
Colorado
5
2015
4116
0.100
 Why?
Organ Specificity
2
2021
273
0.100
 Why?
Biomedical Research
1
2017
589
0.100
 Why?
Oxytocin
1
1992
45
0.100
 Why?
Hepatic Veins
1
2011
31
0.100
 Why?
Cardiac Surgical Procedures
1
2016
415
0.100
 Why?
Remission Induction
3
2008
240
0.100
 Why?
Eponyms
1
1991
1
0.100
 Why?
Esophageal Neoplasms
2
2008
273
0.090
 Why?
Lymphoma, Large B-Cell, Diffuse
2
2009
97
0.090
 Why?
Esophagectomy
1
1992
111
0.090
 Why?
Delphi Technique
2
2022
164
0.090
 Why?
Radiology
1
2014
196
0.090
 Why?
Computer Simulation
3
2012
884
0.090
 Why?
Young Adult
9
2018
10518
0.090
 Why?
Burkitt Lymphoma
1
1991
52
0.090
 Why?
Keratin-18
1
2010
10
0.090
 Why?
Automation
2
2020
74
0.090
 Why?
Surveys and Questionnaires
2
2022
4669
0.090
 Why?
Neoplasm, Residual
1
2010
105
0.090
 Why?
Antibodies, Monoclonal, Humanized
1
2014
667
0.090
 Why?
Respiration
2
2023
177
0.090
 Why?
Meningeal Neoplasms
2
2021
88
0.090
 Why?
History, 20th Century
2
2006
273
0.080
 Why?
Neoplasms, Multiple Primary
1
2010
52
0.080
 Why?
Radiation Dosage
3
2019
139
0.080
 Why?
Immobilization
2
2010
44
0.080
 Why?
Risk Management
2
2020
89
0.080
 Why?
Catheter Ablation
1
2012
291
0.080
 Why?
Caspase 3
1
2010
237
0.080
 Why?
Anthracyclines
1
2009
41
0.080
 Why?
Sex Factors
1
2014
1739
0.080
 Why?
Thoracic Wall
1
2009
15
0.080
 Why?
Rib Fractures
1
2009
24
0.080
 Why?
Neuroblastoma
1
2010
130
0.080
 Why?
Feasibility Studies
4
2016
748
0.080
 Why?
Chest Pain
1
2009
82
0.080
 Why?
Antibiotics, Antineoplastic
1
2009
114
0.080
 Why?
CD8-Positive T-Lymphocytes
3
2009
693
0.080
 Why?
Cross-Priming
1
2008
19
0.080
 Why?
Lymphocyte Count
1
2008
133
0.080
 Why?
Pharyngeal Neoplasms
1
2007
3
0.080
 Why?
Carcinoembryonic Antigen
1
2008
37
0.080
 Why?
Treatment Failure
4
2014
332
0.080
 Why?
Carcinoma, Merkel Cell
1
2008
17
0.080
 Why?
Bile Duct Diseases
1
2008
17
0.080
 Why?
Ki-67 Antigen
1
2008
104
0.080
 Why?
Malaria Vaccines
1
2007
6
0.070
 Why?
Statistics, Nonparametric
2
2018
391
0.070
 Why?
Hemocyanins
1
2007
57
0.070
 Why?
Pancreatic Neoplasms
1
2014
722
0.070
 Why?
Laryngeal Neoplasms
1
2007
27
0.070
 Why?
Photons
1
2008
57
0.070
 Why?
Bile Ducts, Intrahepatic
1
2008
49
0.070
 Why?
Cholestasis, Intrahepatic
1
2008
40
0.070
 Why?
Software
1
2012
541
0.070
 Why?
Cell Line, Tumor
3
2010
2751
0.070
 Why?
Fluorouracil
1
2008
151
0.070
 Why?
Deoxycytidine
1
2008
140
0.070
 Why?
Mouth Neoplasms
1
2007
70
0.070
 Why?
T-Lymphocytes, Cytotoxic
1
2008
156
0.070
 Why?
Accreditation
2
2022
78
0.070
 Why?
DNA Repair
1
2008
190
0.070
 Why?
Pulmonary Disease, Chronic Obstructive
1
2015
1098
0.070
 Why?
Antigen Presentation
1
2007
189
0.070
 Why?
Quality Assurance, Health Care
1
2009
315
0.070
 Why?
Urinary Tract
1
2006
37
0.070
 Why?
Receptors, Antigen, T-Cell, alpha-beta
1
2008
309
0.070
 Why?
Postoperative Nausea and Vomiting
1
2006
10
0.070
 Why?
Adjuvants, Immunologic
1
2007
206
0.070
 Why?
Reproducibility of Results
4
2016
2824
0.070
 Why?
Hodgkin Disease
1
2008
118
0.070
 Why?
Oligopeptides
1
2008
248
0.070
 Why?
Cisplatin
2
2011
263
0.070
 Why?
Whole Body Imaging
1
2006
25
0.070
 Why?
Vertigo
1
2006
36
0.070
 Why?
DNA Damage
1
2008
357
0.070
 Why?
Intestines
1
2009
324
0.070
 Why?
Cranial Nerve Diseases
1
2006
42
0.070
 Why?
Heart Diseases
1
2009
331
0.060
 Why?
History, 21st Century
1
2006
162
0.060
 Why?
Physics
4
2010
18
0.060
 Why?
Heart
2
2020
610
0.060
 Why?
Kidney
2
2010
1207
0.060
 Why?
Light
1
2008
337
0.060
 Why?
Immunotherapy
1
2009
479
0.060
 Why?
Brain
3
2022
2373
0.060
 Why?
Medical Records
3
2010
157
0.060
 Why?
Cell Proliferation
2
2010
2194
0.060
 Why?
Receptor, ErbB-2
2
2019
302
0.060
 Why?
Pilot Projects
2
2001
1384
0.060
 Why?
Bevacizumab
2
2015
118
0.060
 Why?
Adolescent
6
2018
17922
0.060
 Why?
Interferon-gamma
1
2007
726
0.060
 Why?
Body Burden
1
2003
5
0.060
 Why?
Maximum Allowable Concentration
1
2003
14
0.060
 Why?
Cell Count
2
1995
305
0.060
 Why?
Costs and Cost Analysis
2
2001
200
0.060
 Why?
Abdomen
1
2023
104
0.050
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2006
242
0.050
 Why?
Forecasting
2
2017
334
0.050
 Why?
Antibodies, Monoclonal
1
2009
1265
0.050
 Why?
Vasopressins
2
1993
57
0.050
 Why?
Certification
2
2015
90
0.050
 Why?
Peptides
1
2007
864
0.050
 Why?
Electrodes
1
2022
101
0.050
 Why?
Research Design
2
2018
946
0.050
 Why?
Pulmonary Gas Exchange
1
2002
113
0.050
 Why?
Comorbidity
2
2017
1473
0.050
 Why?
Parotid Gland
1
2001
25
0.050
 Why?
Mastectomy
1
2022
99
0.050
 Why?
Oxygen Consumption
2
2016
573
0.050
 Why?
Proto-Oncogene Proteins c-raf
2
1998
43
0.050
 Why?
Apoptosis
1
2010
2377
0.050
 Why?
Rats
3
2002
5033
0.050
 Why?
Hepatitis B
1
2001
53
0.050
 Why?
Carboplatin
2
2011
139
0.050
 Why?
Probability
1
2001
294
0.050
 Why?
Skull Neoplasms
1
2000
21
0.050
 Why?
Camptothecin
2
2011
97
0.050
 Why?
Alveolar Process
1
2000
6
0.040
 Why?
Maxilla
1
2000
29
0.040
 Why?
Patient Positioning
1
2020
43
0.040
 Why?
Palate
1
2000
27
0.040
 Why?
Hospitals, Community
1
2000
47
0.040
 Why?
Canada
1
2021
335
0.040
 Why?
Mouth Mucosa
1
2000
79
0.040
 Why?
Practice Patterns, Physicians'
1
2008
1180
0.040
 Why?
Meningioma
1
2000
78
0.040
 Why?
APACHE
1
1999
59
0.040
 Why?
Health Care Rationing
1
1999
47
0.040
 Why?
Enzyme Activation
2
1998
793
0.040
 Why?
Dexamethasone
2
2012
316
0.040
 Why?
Europe
1
2020
336
0.040
 Why?
Ontario
1
1999
108
0.040
 Why?
Lymphopenia
1
2019
50
0.040
 Why?
Workflow
1
2020
136
0.040
 Why?
Fibrosarcoma
1
1999
20
0.040
 Why?
Reoperation
2
2012
525
0.040
 Why?
Hepatitis C
1
2001
229
0.040
 Why?
Leukocyte Count
1
2019
294
0.040
 Why?
Neutropenia
1
2019
127
0.040
 Why?
Egtazic Acid
1
1998
44
0.040
 Why?
Safety
1
2000
298
0.040
 Why?
Cell Line
2
2008
2651
0.040
 Why?
Tetradecanoylphorbol Acetate
1
1998
153
0.040
 Why?
Education, Medical, Graduate
1
2022
376
0.040
 Why?
Triage
1
2020
192
0.040
 Why?
Immune System
1
2019
173
0.040
 Why?
Fatal Outcome
1
1998
286
0.040
 Why?
Tyrphostins
1
1997
14
0.040
 Why?
Neurosurgeons
1
2017
13
0.040
 Why?
Patient Admission
1
1999
175
0.040
 Why?
Headache
1
1998
131
0.040
 Why?
Academic Medical Centers
1
2000
414
0.040
 Why?
Tumor Cells, Cultured
2
1997
850
0.040
 Why?
Lymphocytes
1
2019
344
0.040
 Why?
Medicaid
1
2021
411
0.040
 Why?
Carbon Dioxide
1
1999
211
0.040
 Why?
Betacoronavirus
1
2020
254
0.040
 Why?
Program Evaluation
1
2021
836
0.030
 Why?
Syndrome
2
2008
339
0.030
 Why?
Protein Kinase C
1
1998
274
0.030
 Why?
Movement
2
2010
246
0.030
 Why?
Curriculum
1
2022
855
0.030
 Why?
Biopsy
1
2000
1056
0.030
 Why?
Neurosurgical Procedures
1
2017
157
0.030
 Why?
National Institutes of Health (U.S.)
1
2016
107
0.030
 Why?
Contrast Media
1
1998
369
0.030
 Why?
Abdominal Neoplasms
1
2015
26
0.030
 Why?
Rats, Inbred F344
2
1993
245
0.030
 Why?
Causality
1
2016
106
0.030
 Why?
Seizures
1
1998
344
0.030
 Why?
Mutation
2
2019
3364
0.030
 Why?
Ions
1
2015
61
0.030
 Why?
Medically Uninsured
1
2016
122
0.030
 Why?
Antineoplastic Agents, Hormonal
1
2016
139
0.030
 Why?
Postoperative Complications
1
2006
2164
0.030
 Why?
Carbazoles
1
2015
80
0.030
 Why?
Age Distribution
1
2016
341
0.030
 Why?
Patient Education as Topic
2
2010
686
0.030
 Why?
Sulfones
1
2015
98
0.030
 Why?
Communication
1
2020
750
0.030
 Why?
Length of Stay
1
1999
958
0.030
 Why?
Myocardium
1
2020
926
0.030
 Why?
Doxorubicin
2
2008
290
0.030
 Why?
Netherlands
1
2014
64
0.030
 Why?
North Carolina
1
2014
97
0.030
 Why?
Sigmoid Neoplasms
1
1994
3
0.030
 Why?
Vital Capacity
1
2015
277
0.030
 Why?
Critical Illness
1
1999
645
0.030
 Why?
Texas
1
2014
187
0.030
 Why?
Trastuzumab
1
2014
89
0.030
 Why?
Models, Theoretical
1
2018
520
0.030
 Why?
Models, Statistical
1
2018
606
0.030
 Why?
Neutrophils
1
2019
1172
0.030
 Why?
Spatial Analysis
1
2013
20
0.030
 Why?
Socioeconomic Factors
1
2017
1086
0.030
 Why?
Forced Expiratory Volume
1
2015
516
0.030
 Why?
Erythrocyte Deformability
1
1993
12
0.030
 Why?
Monte Carlo Method
1
2013
140
0.030
 Why?
Choice Behavior
1
2014
159
0.030
 Why?
Cell Cycle
1
1995
546
0.030
 Why?
Animals
5
2010
32104
0.030
 Why?
Medical Errors
1
2013
84
0.030
 Why?
Rheology
1
1993
88
0.030
 Why?
Fiducial Markers
1
2012
8
0.030
 Why?
Regression Analysis
1
2015
959
0.030
 Why?
Neurophysins
1
1992
5
0.030
 Why?
Mammary Neoplasms, Experimental
1
1992
64
0.030
 Why?
Arginine Vasopressin
1
1992
46
0.030
 Why?
Nucleic Acid Hybridization
1
1992
189
0.020
 Why?
Hydrogen-Ion Concentration
1
1993
515
0.020
 Why?
Longitudinal Studies
1
2018
2420
0.020
 Why?
Genomics
1
2016
646
0.020
 Why?
DNA, Neoplasm
1
1992
157
0.020
 Why?
Diagnosis, Differential
1
2015
1357
0.020
 Why?
Lactic Acid
1
1993
275
0.020
 Why?
Protein Precursors
1
1992
119
0.020
 Why?
Etoposide
1
2011
149
0.020
 Why?
Patient Participation
1
2014
363
0.020
 Why?
Fibrosis
1
2013
457
0.020
 Why?
Case-Control Studies
1
2018
3037
0.020
 Why?
Africa
1
1991
96
0.020
 Why?
X-Linked Inhibitor of Apoptosis Protein
1
2010
12
0.020
 Why?
Retreatment
1
2010
70
0.020
 Why?
Amino Acid Chloromethyl Ketones
1
2010
22
0.020
 Why?
Carmustine
1
2010
47
0.020
 Why?
United Kingdom
1
1991
227
0.020
 Why?
Cysteine Proteinase Inhibitors
1
2010
45
0.020
 Why?
Paclitaxel
1
2011
192
0.020
 Why?
Vincristine
1
2010
96
0.020
 Why?
In Situ Nick-End Labeling
1
2010
119
0.020
 Why?
Palliative Care
2
2012
642
0.020
 Why?
Caspase Inhibitors
1
2010
78
0.020
 Why?
Immunoblotting
1
2010
281
0.020
 Why?
Physical Phenomena
2
1999
12
0.020
 Why?
Kinetics
1
1993
1569
0.020
 Why?
Lymphatic Irradiation
1
2009
9
0.020
 Why?
Urination Disorders
1
2009
11
0.020
 Why?
Logistic Models
1
2014
1856
0.020
 Why?
Cystitis
1
2009
20
0.020
 Why?
Proto-Oncogene Proteins c-bcl-2
1
2010
214
0.020
 Why?
Severity of Illness Index
1
1997
2586
0.020
 Why?
Hepatic Veno-Occlusive Disease
1
2008
10
0.020
 Why?
Neuropsychological Tests
1
2013
920
0.020
 Why?
Ipilimumab
1
2009
28
0.020
 Why?
Nephrectomy
1
2010
150
0.020
 Why?
Prostheses and Implants
1
2010
140
0.020
 Why?
Anti-Inflammatory Agents
1
2012
448
0.020
 Why?
RNA Interference
1
2010
438
0.020
 Why?
Premedication
1
2008
36
0.020
 Why?
Capecitabine
1
2008
46
0.020
 Why?
Administration, Oral
1
2010
734
0.020
 Why?
Models, Animal
1
2010
350
0.020
 Why?
Smoking
1
2015
1457
0.020
 Why?
Enzyme-Linked Immunosorbent Assay
1
2010
795
0.020
 Why?
Mental Status Schedule
1
2007
34
0.020
 Why?
Antimetabolites, Antineoplastic
1
2008
83
0.020
 Why?
Cyclophosphamide
1
2008
218
0.020
 Why?
Hemodynamics
1
1992
1024
0.020
 Why?
Blotting, Western
1
2010
1153
0.020
 Why?
Forearm
1
2008
114
0.020
 Why?
HIV Infections
1
2001
2474
0.020
 Why?
Prednisone
1
2008
232
0.020
 Why?
Diarrhea
1
2008
173
0.020
 Why?
Clinical Trials, Phase II as Topic
1
2007
58
0.020
 Why?
Pain Measurement
1
2009
449
0.020
 Why?
Medical History Taking
1
2007
114
0.020
 Why?
Tomography, Spiral Computed
1
2006
24
0.020
 Why?
Tumor Suppressor Protein p53
1
2010
449
0.020
 Why?
Cognition
1
2013
981
0.020
 Why?
Glucocorticoids
1
2010
552
0.020
 Why?
Pedigree
1
2007
468
0.020
 Why?
Epitopes
1
2008
438
0.020
 Why?
Guideline Adherence
1
2010
497
0.020
 Why?
Cells, Cultured
1
1993
3914
0.020
 Why?
Antiemetics
1
2005
32
0.020
 Why?
Spinal Cord Neoplasms
1
2004
40
0.010
 Why?
Amino Acid Sequence
1
2008
2000
0.010
 Why?
Testosterone
1
2007
337
0.010
 Why?
Disease Models, Animal
1
1993
3580
0.010
 Why?
Esthetics
1
2003
37
0.010
 Why?
Mastectomy, Segmental
1
2003
76
0.010
 Why?
Molecular Sequence Data
1
2008
2790
0.010
 Why?
Carcinoma, Intraductal, Noninfiltrating
1
2003
50
0.010
 Why?
Carcinoma, Lobular
1
2003
44
0.010
 Why?
Spinal Cord
1
2005
351
0.010
 Why?
Carcinoma, Ductal, Breast
1
2003
76
0.010
 Why?
Signal Transduction
2
2010
4541
0.010
 Why?
Craniotomy
1
2000
67
0.010
 Why?
Transplantation, Autologous
1
2000
173
0.010
 Why?
Iridium Radioisotopes
1
1999
6
0.010
 Why?
Skull
1
2000
117
0.010
 Why?
Antisickling Agents
1
1999
5
0.010
 Why?
Cobalt Radioisotopes
1
1999
6
0.010
 Why?
Surgical Flaps
1
2000
121
0.010
 Why?
Tumor Stem Cell Assay
1
1999
33
0.010
 Why?
Oxyhemoglobins
1
1999
19
0.010
 Why?
Neoplasm Invasiveness
1
2000
445
0.010
 Why?
Allosteric Regulation
1
1999
84
0.010
 Why?
Mice, Inbred C3H
1
1999
244
0.010
 Why?
Phosphotyrosine
1
1997
33
0.010
 Why?
Inositol 1,4,5-Trisphosphate
1
1997
27
0.010
 Why?
Phospholipase C gamma
1
1997
26
0.010
 Why?
Type C Phospholipases
1
1997
66
0.010
 Why?
Radiation, Ionizing
1
1997
73
0.010
 Why?
Nitriles
1
1997
152
0.010
 Why?
Hemoglobins
1
1999
312
0.010
 Why?
Pulmonary Circulation
1
1999
410
0.010
 Why?
Isoenzymes
1
1997
285
0.010
 Why?
Bronchial Neoplasms
1
1995
14
0.010
 Why?
Child
2
2008
18503
0.010
 Why?
Child, Preschool
1
2008
9138
0.010
 Why?
Enzyme Inhibitors
1
1997
757
0.010
 Why?
Endometrial Neoplasms
1
1995
151
0.010
 Why?
Postoperative Period
1
1994
293
0.010
 Why?
Neoplasm Transplantation
1
1992
235
0.010
 Why?
Microcirculation
1
1992
138
0.010
 Why?
Mice
1
1999
15052
0.000
 Why?
Kavanagh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (624) concept(s)
_
Co-Authors Expand Description
See all (50) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)